Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022
Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating Runway
https://finance.yahoo.com/news/design-therapeutics-highlights-upcoming-milestones-200500801.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.